Clinical Trial Detail

NCT ID NCT02411656
Title Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center
Indications

triple-receptor negative breast cancer

inflammatory breast carcinoma

Therapies

Pembrolizumab

Age Groups: senior adult

Additional content available in CKB BOOST